You are herePAEDIATRIC FORMULATIONS OR EXTEMPORANEOUS DOSAGE FORM FOR ORAL LIQUIDS
PAEDIATRIC FORMULATIONS OR EXTEMPORANEOUS DOSAGE FORM FOR ORAL LIQUIDS
Preparation of a Extemporaneous preparation-A Guide
• Consider an alternative drug.
• Consider an alternative method, for example, tablet dispersion or oral administration of the injection.
• Consult the latest information data-bases and publications. Prepare a formulation according to a published study and follow the conditions of this study as closely as possible. Modifications to published formulations are only appropriate if there are no detrimental effects on stability. A maximum expiry date of one month from preparation is recommended and liquids without antimicrobial preservative should be given a shorter expiry date. If there are no data from a published study consult pharmaceutical manufacturers, other paediatric hospitals and research centers. It may be possible to adapt existing information from drug stability texts (e.g. solubility, stability profile) or from the formulation details of the injection or oral liquid available elsewhere. Monitor use of the product and observe for any signs of physical instability such as colour change or difficulty in re-suspension. Provide information to carrears to ensure correct use of the product (e.g. storage conditions, use of an oral syringe, shaking before administration). Ensure that formulations details are available to all practitioners involved in the patients care to ensure that the product is consistent in appearance and quality. Prescriptions could contain full details of the formula and hospital pharmacists could provide details to their community colleagues. 
The present article was described a many complex issues that have been described and to highlight some of the factors for pharmacists and paediatricians to consider in order to optimise drug therapy. Information sources such as specialised formularies, drug stability texts and the advice of pharmaceutical companies are invaluable. Most pharmaceutical companies will attempt to provide stability information and can sometimes recommend a specific formulation. Practitioners must continue to lobby for the development and availability of more paediatric oral liquids and paediatric strength tablets some of which may be obtainable in other countries. In order to make information more accessible investigators of clinical drug use should describe the formulation details of the preparation used in their research. This information is often omitted from the publication and can be extremely difficult to source especially when required rapidly. Investigators engaged in stability studies should aim to make the results of their research universally acceptable by designing simple formulations and avoiding the use of unnecessary or difficult to use ingredients. Valid protocol design for the stability study is essential and ideally the study should be carried out on formulations prepared from pure drug as well as tablets and the pure drug formulation used in practice whenever possible. Finally, sharing information on extemporaneous preparation and research collaboration should be further encouraged especially between major paediatric hospitals and research centres to ensure that our patients receive the highest quality drug therapy.
1. Nahata MC, Taketomo e. Pediatrics. In: DIPlroJT, Talbert RL, Yee GC, et aL, eds. Pharmacotherapy: A PathophysIologic Approach. 7th ed. New York, NY: McGraw Hill; 2008: 47-56.
2. Crawford S. Y., Dombrowski S. R. Extemporaneous compounding activities and the associated informational needs of pharmacist. Am J Hosp Pharm; 1991, 48;1205-10.
3. Stewart P. J., Tucker I. G. A survey of current extemporaneously prepared paediatric formulations. Aust J Hosp Pharm; 1982,12(3);64-68.
4. Blumer JL. Off-label uses of drugs In children. Pediatrics. 1999,104;598-602.
5. Pal V, Nahata Me. Need for extemporaneous formulations In pediatric patients. J Pedlatr Pharmacol Ther; 2001,.6;107-119.
6. Nahata MC, Pal VB, Hippie TF. Pediatric Drug Formulations. 5th ed. CinCinnati, OH: Harvey Whitney Books Co; 2003.
7. Milap C. Nahata and Loyd V Allen. Extemporaneous Drug Formulations; Clinical Therapeutics/Volume 30, Number 2008,11, 2112-2120.
8. Joseph F. Standing , Catherine Tuleu. Paediatric formulations—Getting to the heart of the problem. International Journal of Pharmaceutics(2005) 300, 56–66.
9. Ghulam A, Keen K, Tuleu C, et al. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids. Ann Pharmacother. 2007, 41;857-860.
10. The American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients In pharmaceutical products: Update (subject review). Pediatrics. 1997, 99;268-278.
11. Pawar S, Kumar A. Issues In the formulation of drugs for oral use In children: Role of eXCIplents. Paedlatr Drugs2002, 4;371-379.
12. Standing JF, Khaki ZF, Wong Ie. Poor formulation information In published pediatric drug trials. Pediatrics2005, 116; 559-562.
13. Haase M, Luedtke S, Robles J, et al. Evalutlon of dosage form information provided In pediatric drug trial reports. IntJ Phar Compound. In press.
14. Connors K. A. Amidon G. L., Stella V. J. Chemical Stability of Pharmaceuticals. New York: John Wiley, 1986.
15. Van Scoik K. Azathioprine. In: Connors K. A. Amidon G. L., Stella V. J. Chemical Stability of Pharmaceuticals. New York: John Wiley, 1986.
16. Jain N. B. Captopril. In: Connors K. A., Amidon G. L., Stella V. J. Chemical Stability of Pharmaceuticals, 2nd Ed. New York: John Wiley, 1986: 284-89.
17. Stewart B. Methyldopa In: Connors K. A., Amidon G. L., Valentino S. J. Chemical Stability of Pharmaceuticals, New York: John Wiley, 1986: 573-9.
18. Van Scoik 1986(i): 6-Mercaptopurine. In: Connors K. A., Amidon G. L., Stella V. J. Chemical Stability of Pharmaceuticals, 2nd Ed. New York, John Wiley, 1986: 544-47.
19. Alexander K. S., Haribhakti R. P., Parker G. A. Stability of acetazolamide in suspension compounded from tablets. Am J Hosp Pharm 1991, 48; 1241-4.
20. Longer M. A. In: Connors K. A., Amidon G. L., Stella V. J. Chemical Stability of Pharmaceuticals. New York: John Wiley, 1986: 345-50.
21. Addicks W. Furosemide. In: Connors K. A., Amidon G. L., Stella V. J. Chemical Stability of Pharmaceuticals. New York: John Wiley, 1986: 474-77.
22. Hugo W. B., Russell A. D. (Eds). Pharmaceutical Microbiology, 4th Edition, Blackwell, 1987.
23. Tucker I. G., Geddes J. A., Stewart P. J. Dose variations from an extemporaneously prepared chlorothiazide suspension. Aust J Hosp Pharm1982,12;59-63.
24. Musgrove B. S., Miwa L. J. Excessively thick extemporaneous spironolactone suspension. Am J Hosp Pharm 1989, 46; 486.
25. Fawcett J. P., Stark G., Tucker I. G., Woods D. J. Stability of dantrolene oral suspension prepared from capsules. J Clin Pharm Ther1994 I, 19; 349-53.
26. Johnson, D.A., Roach, A.C., Carlsson, A.S., Karlsson, A.A., Behr, D.E.; Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages. Pharmacotherapy2003,23;731–734.
27. Carrier, M.N., Garinot, O., Vitzling, C., Stability and compatibilityof tegaserod from crushed tablets mixed in beverages and foods. Am. J. Health Syst. Pharm. 2004, 61;1135–1142.
28. Yamreudeewong,W., Danthi, S.N., Hill, R.A., Fox, J.L., Stability of ondansetron hydrochloride injection in various beverages. Am. J. Health Syst. Pharm. 1995;52; 2011–2014.
29. Nahata, M.C., Stability of labetalol hydrochloride in distilled water, simple syrup, and three fruit juices. DICP 1991,25;465–469.
30. Imatinib SPC (Summary of Product Characteristics) (Glivec tablets), 2004. Novartis Pharmaceuticals UK Ltd. Last updated on 14th September 2004; available from URL: http://www.emc. medicines.org.uk.
31. Notterman, D.A., Nardi, M., Saslow, J.G., Effect of dose formulation on isoniazid absorption in two young children. Pediatrics1986, 77; 850–852.
32. Tuleu, C., Grang´e, J., Seurin, S, in press. The need for paediatric formulation: oral administration of nifedipine in children, a proof of concept. J. Drug Dev. Sci. Tech..
33. Anonymous, Boots pharmacist and trainee cleared of baby’s manslaughter. Pharm. J. 2000,264; 390–392.
34. Joseph F. Standing , Catherine Tuleu. Paediatric formulations—Getting to the heart of the problem. International Journal of Pharmaceutics(2005) 300 , 56–66.
35. Teng, J., Song, C.K.,Williams, R.L., Polli, J.E.; Lack of medication dose uniformity in commonly split tablets. J. Am. Pharm. Assoc. 2002,42; 195–199.
36. Breitkreutz, J., Wessel, T., Boos, J., Dosage forms for peroral drug administration to children. Paediatr. Perinatal Drug Ther. 1999, 3, 25–33.
37. Anderson, B.J., McKee, A.D., Holford, N.H., Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 1997, 33, 313–327.
38. Streif, W., Andrew, M., Marzinotto, V., Massicotte, P., Chan, A.K., Julian, J.A., Mitchell, L., Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood1999, 94, 3007–3014.
39. Blaszak, R.T., Savage, J.A., Ellis, E.N., The use of short-acting nifedipine in pediatric patients with hypertension. J. Pediatr. 2001,139, 34–37.
40. Tallian, K.B., Nahata, M.C.,Turman, M.A., Mahan, J.D., Hayes, J.R., Mentser, M.I., Efficacy of amlodipine in pediatric patients with hypertension. Pediatr. Nephrol1999, 13, 304–310.
41. Flynn, J.T., Smoyer, W.E., Bunchman, T.E., Treatment of hypertensive children with amlodipine. Am. J. Hypertens. 2000, 13, 1061–1066.
42. Standing, J.F., Wong, I.C., Chlorproguanil-dapsone for malaria. Lancet 2004,364, 1752–1753.
43. Milap C. Nahata and Loyd V Allen. Extemporaneous Drug Formulations; Clinical Therapeutics/2008,Volume 30, Number 11, 2112-2120.
44. David J Woods . Extemporaneous formulations of Oral Liquids A Guide David J Woods.
http://www.pharminfotech.co.nz/manual/Formulation/extemprep.pdf accesed on2011, 12 February
Reference ID: PHARMATUTOR-ART-1046
FIND OUT MORE ARTICLES AT OUR DATABASE